1. Badve, S., Dabbs, D., Schnitt, S., Baehner, F., Decker, T., Eusebi, V., et al. (2010). Basal-like and triple-negative breast cancers: A critical review with an emphasis on the implications for pathologists and oncologists. Modern Pathology, 24, 157–167.
2. Bertucci, F., Finetti, P., Cervera, N., Charafe-Jauffret, E., Mamessier, E., Adélaïde, J., et al. (2006). Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Research, 66, 4636–4644.
3. Dua, I., & Tan, A. R. (2017). Immunotherapy for triple-negative breast cancer: A focus on immune checkpoint inhibitors. American Journal of Haematology and Oncology, 13, 20–27.
4. Eisinger, F., Noguès, C., Birnbaum, D., Jacquemier, J., & Sobol, H. (1998). BRCA1 and medullary breast cancer. Journal of the American Medical Association, 280, 1227–1228.
5. Ellis, I. O., Al-Sam, S., Anderson, N., Carder, P., Deb, R., Girling, A., et al. (2016). Pathology reporting of breast disease in surgical excision specimens incorporating the dataset for histological reporting of breast cancer. (2016). Rcpath.org. Available from:
http://www.rcpath.org
. Accessed Sept 2017.